Amniotic Fluid With TIMPs for Chronic Wound Protease Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chronic wounds, particularly those with elevated protease activity, do not heal effectively with current treatment methods, leading to prolonged inflammation and potential amputation.
Innovation Solution
Application of human amniotic fluid containing a therapeutically effective amount of tissue inhibitors of matrix metalloproteinases (TIMPs) to inhibit protease activity and promote healing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatment methods (antibiotics, NSAIDs, surgical debridement, HBO, topical chemicals, collagen dressings) are used to treat chronic wounds, then some wound care functions are provided, but the wounds fail to heal effectively due to elevated protease activity
Solution Approach 1:
The patent applies TIMPs (tissue inhibitors of metalloproteinases) to counteract the harmful elevated protease activity in chronic wounds. By introducing these specific inhibitors, the treatment converts the harmful proteolytic environment into a beneficial one that supports healing, directly addressing the root cause of treatment failure in EPA wounds
Solution Approach 2:
The patent changes the biochemical parameter of protease activity in the wound environment by applying TIMPs. This alters the wound's proteolytic balance from an elevated, healing-inhibiting state to a controlled state that permits progression through healing stages, thereby improving healing effectiveness
2Reliability
If collagen wound dressings are applied to compete with proteases, then substrate competition is provided, but healing efficacy remains insufficient
Solution Approach 1:
The patent introduces TIMPs as intermediary substances that specifically bind to and inhibit metalloproteinases. These TIMPs act as mediators between the harmful proteases and the healing process, providing more effective inhibition than collagen substrate competition alone
3Duration of action of moving object
If wounds remain in the inflammatory stage too long, then inflammation provides initial wound response, but progression to healing stages is prevented
Solution Approach 1:
The patent employs TIMPs to provide feedback control over protease activity during wound healing. By regulating MMP levels, TIMPs create a feedback mechanism that allows the wound to transition from the inflammatory stage to proliferative and remodeling stages, preventing indefinite stalling in any single stage
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Amniotic fluid with TIMPs facilitates wound healing by inhibiting elevated protease activity, promoting epithelial cell proliferation, and restoring the wound healing process to its normal stages, reducing symptoms and potentially leading to complete healing.
Implementation Method 1
amniotic fluid having elevated levels of tissue inhibitors of matrix metalloproteinases
Data Source
AI summary
Methods for treating chronic wounds with an amniotic fluid having a therapeutically effective amount of tissue inhibitors of matrix metalloproteinases (TIMPs) are described. The amniotic fluid can be obtained from a female donor during a period of gestation when the concentration of endogenous TIMPs are at or near their maximum level. The methods described herein are particularly useful for promoting wound healing in chronic wounds having elevated protease activity, such as increased amounts or specific activity of matrix metalloproteinases.